Trial Profile
A Multi-Center, Randomized, Parallel Group, Double-Blind, Vehicle-Controlled Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel, 0.015% In Patients With Actinic Keratoses ON the Head (Face or Scalp) (REGION-IIa).
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 31 Mar 2016
Price :
$35
*
At a glance
- Drugs Ingenol mebutate (Primary)
- Indications Actinic keratosis; Skin cancer
- Focus Registrational; Therapeutic Use
- Acronyms REGION-IIa
- Sponsors Peplin
- 08 Mar 2016 Results (n=220) of a regression analysis from this and other trial (see profile 46217) presented at the 74th Annual Meeting of the American Academy of Dermatology
- 20 Mar 2012 Pooled analysis and tolerability results presented at the 70th Annual Meeting of the American Academy of Dermatology.
- 20 Mar 2012 Pooled tolerability analysis assessing local skin responses presented at the 70th Annual Meeting of the American Academy of Dermatology.